Receipt of Section 249D Notice from BCAL Diagnostics
Filed with ASX · · 1 page · English
Summary by 6ix AI
The company is currently evaluating the validity of this notice and will comply with its obligations under the Corporations Act if deemed valid. This announcement is made in accordance with ASX Listing Rule requirements.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Genetic Signatures' latest callGenetic Signatures (ASX:GSS) Q4 2026 Earnings Call · Replay · Aug 25Read the transcript of Genetic Signatures (ASX:GSS) Q4 2026 Earnings CallGenetic Signatures Ltd. on 6ix
Story so far
Earlier from Genetic Signatures
- Date of AGM and Closing Date for Director Nominations
- BDX Holdings of GSS Shares and receipt of Section 249D
- Final Director's Interest Notice
- Board Changes
- Ceasing to be a substantial holder
Later from Genetic Signatures
- GSS and MAP agree to Commercial Terms for Merger
- GSS Investor Presentation - Proposed Merger with MAP
- Notice of Extraordinary General Meeting
- Becoming a substantial holder
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Genetic Signatures into a list and get an email when it puts out news.
Follow Genetic Signatures